These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 12955350)

  • 41. Influence of mismatching of HLA cross-reactive groups on cadaveric kidney transplantation.
    Hwang SH; Oh HB; Shin ES; Yew M; Kim SC; Han DJ
    Transplant Proc; 2005 Dec; 37(10):4194-8. PubMed ID: 16387076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human leukocyte antigens DR and AB and kidney retransplantation.
    Thompson JS; Thacker LR; Krishnan G
    Transplantation; 2003 Mar; 75(5):718-23. PubMed ID: 12640315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone marrow transplantation with unrelated donors: what is the probability of identifying an HLA-A/B/Cw/DRB1/B3/B5/DQB1-matched donor?
    Tiercy JM; Bujan-Lose M; Chapuis B; Gratwohl A; Gmür J; Seger R; Kern M; Morell A; Roosnek E
    Bone Marrow Transplant; 2000 Aug; 26(4):437-41. PubMed ID: 10982291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlations between Terasaki's HLA class I epitopes and HLAMatchmaker-defined eplets on HLA-A, -B and -C antigens.
    Duquesnoy RJ; Marrari M
    Tissue Antigens; 2009 Aug; 74(2):117-33. PubMed ID: 19497041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HLA matching effects.
    Mickey MR
    Clin Transpl; 1987; ():303-16. PubMed ID: 3154423
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Computer program to predict likelihood of finding and HLA-matched donor: methodology, validation, and application.
    Mori M; Graves M; Milford EL; Beatty PG
    Biol Blood Marrow Transplant; 1996 Oct; 2(3):134-44. PubMed ID: 9199756
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker.
    Kosmoliaptsis V; Bradley JA; Sharples LD; Chaudhry A; Key T; Goodman RS; Taylor CJ
    Transplantation; 2008 Jun; 85(12):1817-25. PubMed ID: 18580476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of the highly sensitized patient.
    Claas FH; Doxiadis II
    Curr Opin Immunol; 2009 Oct; 21(5):569-72. PubMed ID: 19682882
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A model for human leukocyte antigen-matched donor-swap transplantation in India.
    Basu G; Daniel D; Rajagopal A; Neelakantan N; John GT
    Transplantation; 2008 Mar; 85(5):687-92. PubMed ID: 18337661
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renal after cardiothoracic transplant: the effect of repeat mismatches on outcome.
    Caskey FJ; Johnson RJ; Fuggle SV; Start S; Pugh D; Dudley CR
    Transplantation; 2009 Jun; 87(11):1727-32. PubMed ID: 19502967
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HLAMatchmaker-based analysis of human monoclonal antibody reactivity demonstrates the importance of an additional contact site for specific recognition of triplet-defined epitopes.
    Duquesnoy RJ; Mulder A; Askar M; Fernandez-Vina M; Claas FH
    Hum Immunol; 2005 Jul; 66(7):749-61. PubMed ID: 16112022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications.
    Duquesnoy RJ
    Tissue Antigens; 2011 Jun; 77(6):525-34. PubMed ID: 21410655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients.
    Heidt S; Haasnoot GW; van Rood JJ; Witvliet MD; Claas FHJ
    Kidney Int; 2018 Feb; 93(2):491-500. PubMed ID: 28947279
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Public epitope specificity of HLA class I antibodies induced by a failed kidney transplant: alloantibody characterization by flow cytometric techniques.
    Piazza A; Poggi E; Ozzella G; Borrelli L; Monaco PI; Scornajenghi A; Tisone G; Adorno D
    Transplantation; 2006 May; 81(9):1298-305. PubMed ID: 16699458
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HLA matching by amino acid/positions in double and triple combinations.
    Idica A; Sasaki N; Terasaki P
    Clin Transpl; 2006; ():123-38. PubMed ID: 18365374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A multi-factor analysis of kidney regraft outcomes.
    Gjertson DW
    Clin Transpl; 2002; ():335-49. PubMed ID: 12971460
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extending options for highly sensitized patients to receive a suitable kidney graft.
    Doxiadis II; Duquesnoy RJ; Claas FH
    Curr Opin Immunol; 2005 Oct; 17(5):536-40. PubMed ID: 16084709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Collaborative Transplant Study Kidney Exchange Trial for highly sensitized recipients.
    Opelz G
    Clin Transpl; 1991; ():61-4. PubMed ID: 1820146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unexpected frequencies of HLA antibody specificities present in sera of multitransfused patients.
    Idica A; Sasaki N; Hardy S; Terasaki P
    Clin Transpl; 2006; ():139-59. PubMed ID: 18365375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.